Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO Sells $154,674.70 in Stock

Key Points

• Amylyx Pharmaceuticals' CFO, James Frates, sold 10,558 shares for a total of $154,674.70, reducing his ownership by 3.63%.
• The company reported a loss of ($0.46) earnings per share in its last earnings announcement, missing expectations by $0.02.
• Several analysts upgraded their ratings on Amylyx Pharmaceuticals, with price targets ranging from $12.00 to $25.00, and a consensus rating of "Buy".

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James Frates sold 10,558 shares of the business's stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $14.65, for a total value of $154,674.70. Following the sale, the chief financial officer directly owned 280,430 shares in the company, valued at $4,108,299.50. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Amylyx Pharmaceuticals Trading Down 5.1%

Shares of Amylyx Pharmaceuticals stock traded down $0.71 on Thursday, reaching $13.29. 3,330,605 shares of the company were exchanged, compared to its average volume of 1,254,741. The stock has a fifty day moving average price of $10.09 and a 200-day moving average price of $6.87. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -5.32 and a beta of -0.34. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.02). On average, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AMLX. Citigroup began coverage on Amylyx Pharmaceuticals in a research report on Tuesday, June 17th. They set a "buy" rating and a $12.00 price target on the stock. The Goldman Sachs Group upped their price target on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, September 16th. UBS Group raised Amylyx Pharmaceuticals to a "hold" rating in a research report on Tuesday, June 24th. Guggenheim upped their price target on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, September 15th. Finally, Wall Street Zen raised Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $14.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AMLX. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals in the second quarter valued at about $28,000. Valeo Financial Advisors LLC purchased a new position in Amylyx Pharmaceuticals in the first quarter valued at about $35,000. R Squared Ltd grew its stake in Amylyx Pharmaceuticals by 99.9% in the first quarter. R Squared Ltd now owns 12,736 shares of the company's stock valued at $45,000 after purchasing an additional 6,366 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth about $45,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock worth $47,000 after acquiring an additional 5,904 shares in the last quarter. Hedge funds and other institutional investors own 95.84% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.